Overview

Critics of youth gender medicine often describe social transition as the first step on a pipeline: a "conveyor belt" or "one-way street" that runs from a new name and pronouns, to a firmer trans identity, to puberty blockers, cross-sex hormones and, for some, surgery. Supporters reply that people move through these steps because their identity is real and stable, not because the steps push them along.

This page looks at each point on that pathway separately. For each one it asks two questions: how often do people move on to the next step, and why? It also looks at the forces that can make carrying on easier than stopping, what detransitioners say about being "carried along", how the pathway differs for adolescents and adults, and where people do get off. For what social transition involves and the wider evidence on it, see social transition. For the drugs themselves, see puberty blockers and the medical transition hub.

The pathway at a glance

The table summarises each transition point. The percentages come from different populations, countries and decades, so they cannot be multiplied together into one overall rate. They show how "sticky" each step has been in the studies that exist.

Step 1–2: social transition and identity consolidation

The first link in the chain is the least medical and the hardest to measure. Social transition before clinic assessment used to be rare but is becoming more common (Hall et al. 2024). In the older cohorts, most children stopped being dysphoric by adulthood. In a Toronto follow-up of 139 boys, 87.8% were no longer dysphoric by an average age of 20.6 (Singh et al. 2021).

The Dutch team found that having made a social role transition in childhood was one of the factors associated with dysphoria persisting into adolescence, alongside the intensity of early dysphoria. The effect varied between natal boys and girls (Steensma et al. 2013). In the TransYouth Project, a long-running US study led by psychologist Kristina Olson, every child had socially transitioned, at around age 6.5. About five years later, 94% identified as binary transgender and 2.5% identified with their sex (Olson et al. 2022). By the end of the study about 29% had started puberty blockers and 31% cross-sex hormones (SEGM 2022).

The York systematic review for the Cass Review (the 2024 independent review of NHS gender services for young people in England) found no robust evidence that social transition improves children's mental health. It also found that the evidence on its effect on identity was too weak to settle the question (Hall et al. 2024). The Cass Review concluded that social transition should be seen as an active intervention rather than a neutral act. It recommended that decisions for pre-pubertal children involve experienced clinicians.

How social transition might "lock in" an identity is covered in depth on the social transition page, and the child-specific evidence on young children. For this page the key point is simple. In the studies that exist, early social transition is followed by much higher persistence than was seen without it, and persistence is the gateway to the medical steps.

Step 3–4: puberty blockers to cross-sex hormones

This is the best-documented step, and the one where the "pipeline" description fits the data most closely.

• Netherlands. Of 143 adolescents who started blockers at a Dutch clinic, 125 (87%) had started cross-sex hormones within the follow-up period, after a median of 0.8 years. Nine (6%) stopped blockers, and only five (3.5%) no longer wanted gender treatment. The rest were still on blockers (Brik et al. 2020). The authors noted that because the study was observational, it could not say whether the blockers themselves influenced the outcome.
• England. In the Tavistock's early-intervention study of 44 young people aged 12 to 15, one stopped blockers and 43 (98%) chose to start cross-sex hormones (Carmichael et al. 2021). The same study found no significant change in psychological function on blockers.
• Norway. In a national cohort of 1,258 referred young people, 97% of those who received blockers went on to hormones (Nyquist et al. 2025, retracted 2026).
• Long term. Of 720 Dutch adolescents who took blockers and then hormones, 98% still had a hormone prescription at follow-up. Of the 16 who did not, 75% had already had their gonads removed (van der Loos et al. 2022).

The court and the Cass Review

In 2020 the English High Court, hearing Keira Bell's case, heard evidence that almost all children who started blockers moved on to cross-sex hormones. It treated the two as stages of one clinical pathway rather than separate decisions. It ruled that a child would need to understand the immediate and long-term consequences of the treatment to consent, and that under-16s would very rarely be able to do so (Bell v Tavistock 2020). The Court of Appeal overturned the ruling in 2021. It held that the treatment was lawful and that judging a young person's competence to consent was a matter for clinicians, not the courts (Bell v Tavistock, Court of Appeal 2021).

The Cass Review went further. Blockers were introduced to buy "time to think". Yet nearly everyone who started them went on to hormones, and the review raised the possibility that blockers change the path of psychosexual and identity development rather than pausing it. A 2025 systematic review found the evidence on blockers' benefits to be of very low certainty. It also found bone density lower after treatment (Miroshnychenko et al. 2025).

Selection or cause?

Three explanations for the 87–98% figures, not mutually exclusive:

1. Selection. Clinics only prescribed blockers to young people with intense, persistent dysphoria, who would have gone on to hormones anyway.
2. Consolidation. Blocking the body's own puberty removes the one experience that, in older cohorts, often resolved dysphoria. Meanwhile the young person lives in the new role for years.
3. Pathway momentum. Once a young person, family and clinic have committed to blockers, hormones become the expected next appointment rather than a fresh decision.

No study has compared similar young people with and without blockers to test these against each other. What the data do show is that blockers have very rarely worked as an exit point.

Step 5–6: hormones to surgery

The jump from hormones to surgery is much less automatic. Cost, waiting lists, fear of complications and personal goals all reduce it.

• In the 2015 US Transgender Survey of 27,715 respondents, 49% had received hormones and 25% had had some form of surgery (James et al. 2016, as reported in a 2022 survey paper).
• In a UK adult gender clinic, 94% of those seeking hormones received them. Only 57% of those seeking feminising surgery and 26% of those seeking masculinising surgery had it by discharge. Neurodevelopmental conditions and adverse childhood experiences predicted worse outcomes, and 6.9% met the authors' definition of detransition (Hall et al. 2021).
• In the US, estimated chest surgeries on minors rose from about 100 in 2016 to 489 in 2019 in one national sample. Almost all were mastectomies, and the median age was 16 (Das et al. 2022).

The step is more common for some groups than others. For females who take testosterone, a mastectomy is the usual next step, and detransitioners describe it being offered after a year on testosterone or sooner. Genital surgery is less common for both sexes. For males, orchiectomy and vaginoplasty usually come later, in adulthood.

Timing in r/detrans stories

detrans.ai has analysed about 3,094 detransition and desistance stories from /r/detrans (detrans.ai stats). An AI builds each user's posts into one narrative and extracts the ages they mention, so n varies by milestone. This is a large but self-selected sample, AI extraction can make errors, and the figures are not transition or detransition rates.

Three patterns stand out in the timelines:

• The steps are compressed. Of 816 stories that gave both a transition age and a hormone age, 68% started hormones at the same age they began transitioning, and 76% within a year. In many of these accounts, social transition was not a long trial period before medicine. It ran straight into it.
• Blockers rarely stopped anyone. Of 83 stories with an age for puberty blockers, 81 also gave an age for starting hormones. The number is small, but it matches the clinical cohorts.
• Surgery followed quickly, and so did detransition. Among 200 stories with both ages, top surgery came a median of two years after hormones. Detransition came a median of three years after hormones (n = 599). For many in this sample, irreversible surgery fell within the period they later left.

Across the full cohort, 22% of stories describe social pressure to transition, and 8% say parental or medical pressure contributed (n = 3,094). About 13% describe only a social transition, a reminder that many people get off before any medical step (detrans.ai stats).

Why each step is easier than stopping

Several forces can make the next step feel like the default and stopping feel like the decision that needs justifying. Together they help explain how a series of individually "reversible" choices can add up to an irreversible path.

The "pause button" framing

Blockers were long described as a fully reversible pause. Before June 2020 the NHS website described them as "fully reversible", and the High Court noted the change of wording (Bell v Tavistock 2020). If the first medical step is presented as no real commitment, it is easier to start. Once started, it leads almost always to the next step. The low starting threshold and the high continuation rate are two sides of the same mechanism.

Momentum and compressed timelines

Each step is offered as the natural continuation of the last: new name, then a referral, then blockers, then hormones "as soon as eligible". The Brik cohort started hormones a median of 0.8 years after blockers (Brik et al. 2020). Some detransitioners describe a mastectomy within months of their first testosterone prescription (see below). When steps follow this fast, there is little time between them in which doubts can surface.

Social commitment and identity investment

Coming out to a school, family and online community is a public commitment. Each later step deepens it. Friends, a support group and sometimes an online following come to depend on the identity, and many detransitioners describe losing friends when they stopped. The psychological mechanisms — consistency pressure, sunk costs and identity foreclosure — are discussed on the social transition page. In the medical stages, physical changes add to the sunk cost: after years of testosterone, a deep voice and facial hair make going back feel harder, not easier.

Clinician expectations and affirmative-care protocols

Under the affirmation model, a clinician's role is to support the identity the patient states rather than explore other explanations for distress. A critique of informed consent argues that this turns each step into a service to be delivered rather than a decision to be weighed. In a survey of 100 detransitioners, 55% felt they had not been adequately evaluated before transition (Littman 2021). A 2023 commentary argues that the affirmation model has led to insufficient psychological assessment and to medical risks being downplayed (Jorgensen 2023). Several detransitioners believe clinicians are afraid of being labelled transphobic if they slow a patient down.

Waiting lists and the ticking clock

Long waiting lists can make a place in the queue feel too valuable to give up. They can also push people to private or telehealth prescribers, or to black-market hormones. Many young people also feel that time is against them, because each month of natal puberty or each year of age makes "passing" harder. That urgency works against any pause for reflection.

What detransitioners report

These /r/detrans accounts are not a representative sample, but the same themes recur: being carried along, no one suggesting a pause, and doubts that did not feel allowed.

"A conveyor belt"

It's like knowing you're on a conveyor belt towards an incinerator but everyone is cheering you on to stay. … Plus the immense support makes it seem like the best decision. —Fuck_Everything_Dude, desisted female

A lot of the gender clinics are literally becoming factories, putting patients on a conveyor belt. I’ve seen the 2.5 years on HRT requirement to get MTF surgeries decrease to 1 year. —loveincautionn, detrans male

I was thrilled at each new development I succeeded at. … I really loved it until the milestones eventually stopped and I realized I had been speeding down a highway to a city I never really wanted to live in. —ftmtxyz, detrans female

"It all happened so fast"

In the U.S I only had one visit with a clinic that lasted about 2 hours. A week later they gave me testosterone. 2 months after that I was given a mastectomy. … the doctors were telling them that hormones and surgery would fix everything. —lee_ehrlich, questioning own transition (female)

I was prescribed estrogen and puberty blockers when I was 16. Only two hour long appointments with a psychiatrist at Children's hospital then I was given the green light to start hrt. —Dear-Shift-7636, detrans male

I didn't question taking T at all as it was pushed as the logical next step. When I detransitioned I didn't get the same good vibes... friends disappeared. —plaid_seahorse, desisted female

"Nobody asked me to slow down"

I wish I was slowed down by my doctor and had gotten more support instead to being told that I seemed like a straightforward case of having gender dysphoria and benefiting from transitioning. —MangoProud3126, detrans female

When I told my doctor I was trans, I saw a sudden fear come over them. They were very careful not to question it. … Compare that to when I said I had ADHD. Suddenly it required months of appointments and testing before I could get medication —tophology, desisted male

"Once I started I couldn't stop"

Several accounts describe doubts right up to the operating theatre, and a feeling that it was too late to act on them.

I had doubts right up until the day of the surgery, right in front of the surgical team, but no one seemed to be concerned. —detrans_throwaway11, detrans male

I remember feeling doubt the night before. But I had already paid the surgery fees and couldn't stand to explain/admit that I changed my mind when I'd been so excited about the surgery for years. It was not a sunk cost even though it felt like one. —cancelnotelighty, detrans female

I felt pressured to remove my uterus because the hospital kept rescheduling the appointments I missed and kept calling me urging me to go ahead or my spot on the wait list would be lost —Sad-Comedian-5747, detrans female

i was on hormone blockers for six years, since i was fourteen. i was not old enough to make the decision to be infertile, stop the way my body naturally grows, give myself weekly migraines. —alwaysontheupswing, detrans female

The ticking clock

Part of being trans is a hyper-awareness of an ever ticking clock pushing your body away in the opposite direction to where you want it to go. It can fully override the processes for considered and rational contemplation. There's no time to consider that you might be wrong! —cagedbunny83, detrans male

The same commenter credits 1990s NHS gatekeeping with keeping him from going further down the medical pathway, even though he and his peers protested against it at the time. Another man describes being drawn in by online advice to "transition now, or transition later?", combined with "a real sense of urgency" once he saw how easily it could be started (Guessimagirl, questioning own transition).

Getting off

Not everyone stays on the belt. These accounts describe the off-ramps people found:

I had a top surgery scheduled but decided to cancel it the day before it was supposed to happen because I just had a terrible feeling about it…6 months later now, I am incredibly glad I didn’t do it because I realised I’m not trans . —Aranyary, detrans female

I socially transitioned in grade 10, and detransitioned in grade 12. It was awkward, but nobody really cared that much, and I a felt like a weight was lifted off my shoulders. —grossnweird_, detrans female

after a 3 hour session, the therapist wanted to book an appointment with the endocrinologist to see what my options were to get on HRT. My mom shut that down and found me a therapist to help me with my anxiety. —Ok-Many-4140, socially transitioned, regrets transition

Others got off later. One woman stopped testosterone after two months and said a month of therapy would have stopped her starting (RequirementSimple580, detrans female). Another was saving for a mastectomy and being asked about phalloplasty at 18 when she detransitioned (Lurkersquid, detrans female). See detransition processes and desistance.

Adolescents versus adults

The pipeline argument applies most strongly to adolescents. For them the sequence is built into the protocol: under the Dutch model, blockers in early puberty lead to hormones at around 16 and surgery from 18. Each stage was designed to follow the last. Adolescents also have less life experience to weigh against an identity, depend on parents and schools, and can feel the most urgency because puberty is happening now. Several countries, including England, Sweden and Finland, have since restricted blockers or hormones for minors after their own evidence reviews (see evidence reviews).

For adults there are no blockers and no built-in timetable. Social and medical steps happen in many orders, and many trans adults choose hormones without surgery. Adults can still feel carried along. Detransitioners describe hormones after one telehealth call, or surgery letters after one Zoom session. But the momentum then comes more from clinics, online communities and personal urgency than from a formal protocol. In the US military insurance cohort, people who started hormones as adults were more likely to stop within four years than those who started as minors (64% vs 74% continuation) (Roberts et al. 2022). One reading is that adults face fewer of the forces that keep adolescents on the pathway.

Informed-consent clinics versus gatekept models

How fast someone moves along depends heavily on the type of clinic.

• Gatekept (assessment) models require a diagnosis, often psychological assessment, and in the past a period of "real life experience" in the new role before hormones or surgery. They slow the pathway down. They can also turn social transition into an entry requirement. One commenter describes having to adopt a female presentation and voice training to get hormones, which pushed him into seeing himself as a girl rather than "a boy choosing to feminize himself" (proof_of_ghosts, /r/detrans commenter).
• Informed-consent models prescribe hormones once the patient signs a consent form, often at the first appointment. They remove the gates between steps entirely. The informed consent critique page sets out why some detransitioners see this as consent that was not truly informed.

The two models fail in different ways. Gatekeeping can make a fixed social role the price of medical care. Informed consent can remove the friction that, in several accounts above, would have given doubts time to surface.

Counterpoints

The pipeline description is contested, and a fair account has to include the arguments against it:

• The pathway is not inevitable. In Norway, 22% of referred young people were discharged without medical treatment (Nyquist et al. 2025, retracted 2026). In the US military cohort, 30% had stopped hormones within four years (Roberts et al. 2022). In r/detrans stories, more than one in five describe stopping at or before social transition (detrans.ai stats). Many detransitioners did get off, sometimes after years.
• High continuation may reflect good selection. The Dutch protocol (the Amsterdam clinic's original approach of blockers followed by hormones for adolescents) produced its results in small, carefully screened groups with childhood-onset dysphoria. Supporters argue that high continuation in such groups is what a well-functioning assessment should produce.
• Some adults see the pathway as appropriate care. For adults with long-standing dysphoria, moving from social to medical transition may be a considered choice, and some experience gatekeeping as the main harm (see below).

Against this, the populations have changed. Today's clinics see far more adolescent girls with recent-onset distress and co-occurring conditions (Cass 2024). Most studies of continuation also lose people to follow-up, and only 24% of detransitioners in one survey told their clinicians they had stopped (Littman 2021). High continuation in clinic records may partly reflect who stays in contact.

What trans people describe

Some trans commenters describe social transition as a deliberate test before medical steps, the opposite of a conveyor belt:

Socially, then medically. Always better to have some security in your choice even if you don’t rly feel too great abt it whilst in your social transition phase. —Runescapelegend778, trans woman (MTF)

Others openly see childhood social transition as preparation for medical steps. In answer to a parent of a six-year-old, one trans woman wrote that if the child stayed enthusiastic until puberty, "medical intervention would probably be wise to consider" (MyHouz, trans woman (MTF)). Supporters read this as responsiveness to the child. Critics read it as the pipeline described from the inside.

Many trans people experience assessment as the problem rather than the safeguard:

I also got gatekept hard, spent 2 whole fucking years going to meeting after meeting because I guess I wasn't socially transitioning. —Alice_Oe, trans woman (MTF)

Some describe being asked, as adults, "are you sure?" and being told about risks at every appointment (Birdkiller49, trans man (FTM)). Many also reject the idea that every step is expected of them:

Not every trans person has gender affirming surgery, and not every trans person who doesn’t get surgery opted for that only due to financial reasons. —Acceptable-Cookie-25, trans man (FTM)

These accounts are a reminder that experiences vary. For some adults the steps are separate, chosen decisions. The pipeline concern is strongest where the person is young, the steps are compressed, and no one is exploring other explanations for their distress, such as trauma, autism or internalised homophobia.

Known risks

The table covers the risks that arise from moving through the steps in sequence: harms that build up or only appear when one stage leads into the next. Each intervention's own full risk profile is on its page: puberty blockers, testosterone, estrogen and surgery.

What detransitioners report

The risks people describe most often in r/detrans stories are the ones the table can only summarise: hormone or body-change regret (26% of stories), medical complications (33%) and irreversible changes (35%) (n = 3,094, detrans.ai stats). In the accounts quoted above, the harm was often not one decision but the speed at which one led to the next.

Unknowns

Several key questions have never been answered:

• Whether social transition or blockers cause higher persistence, or simply mark it. No controlled comparison exists.
• How many people who moved through the whole pathway in adolescence later regret it. Most follow-ups end in the early twenties, while detransition in r/detrans stories peaks around age 21 and continues well beyond it.
• Long-term outcomes for the current population: mostly female, adolescent-onset, with high rates of co-occurring conditions.
• Whether clinics with built-in pauses, such as exploratory therapy before each step, would change continuation rates. See gender-exploratory therapy.

Further reading

See the sibling pages on young children, schools and parents and names and pronouns; transition regret; the study archive and detransition videos; and the support directory of gender-exploratory therapists and detrans support groups.

References

• Brik, T., et al. (2020). Trajectories of adolescents treated with gonadotropin-releasing hormone analogues for gender dysphoria. Archives of Sexual Behavior, 49, 2611–2618. source.
• Carmichael, P., Butler, G., Masic, U., et al. (2021). Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLOS ONE, 16(2), e0243894. source.
• Cass, H. (2024). Independent review of gender identity services for children and young people: Final report. study page, source.
• Das, R. K., Perdikis, G., Al Kassis, S., & Drolet, B. C. (2022). Gender-affirming chest reconstruction among transgender and gender-diverse adolescents in the US from 2016 to 2019. JAMA Pediatrics, 177(1), 89–90. source.
• Hall, R., Mitchell, L., & Sachdeva, J. (2021). Access to care and frequency of detransition among a cohort discharged by a UK national adult gender identity clinic. BJPsych Open. study page, source.
• Hall, R., Taylor, J., Hewitt, C. E., et al. (2024). Impact of social transition in relation to gender for children and adolescents: a systematic review. Archives of Disease in Childhood, 109(Suppl 2), s12–s18. source.
• High Court of England and Wales (2020). R (Bell) v Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274 (Admin). judgment.
• Court of Appeal of England and Wales (2021). Bell v Tavistock [2021] EWCA Civ 1363. judgment.
• Jorgensen, S. C. J. (2023). Iatrogenic harm in gender medicine. Journal of Sex & Marital Therapy. study page, source.
• Anonymous US survey (2022). Preferences for and barriers to gender affirming surgeries in transgender and non-binary individuals (reporting 2015 US Transgender Survey figures, James et al. 2016). source.
• Littman, L. (2021). Individuals treated for gender dysphoria with medical and/or surgical transition who subsequently detransitioned: a survey of 100 detransitioners. Archives of Sexual Behavior. study page, source.
• Miroshnychenko, A., et al. (2025). Puberty blockers for gender dysphoria in youth: a systematic review and meta-analysis. Archives of Disease in Childhood. study page, source.
• Miroshnychenko, A., et al. (2025). Gender affirming hormone therapy for individuals with gender dysphoria aged <26 years: a systematic review and meta-analysis. Archives of Disease in Childhood. study page, source.
• Nyquist, C. B., Torgersen, L., David, L. W., et al. (2025). Treatment trajectories among children and adolescents referred to the Norwegian National Center for Gender Incongruence. study page, source.
• Olson, K. R., et al. (2022). Gender identity 5 years after social transition. Pediatrics, 150(2), e2021056082. source.
• Roberts, C. M., Klein, D. A., Adirim, T. A., Schvey, N. A., & Hisle-Gorman, E. (2022). Continuation of gender-affirming hormones among transgender adolescents and adults. Journal of Clinical Endocrinology & Metabolism. study page, source.
• SEGM (2022). Early social gender transition in children is associated with high rates of transgender identity in early adolescence. source.
• Singh, D., Bradley, S. J., & Zucker, K. J. (2021). A follow-up study of boys with gender identity disorder. study page.
• Steensma, T. D., McGuire, J. K., Kreukels, B. P. C., Beekman, A. J., & Cohen-Kettenis, P. T. (2013). Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry, 52(6), 582–590. source.
• US Food and Drug Administration / AbbVie. Lupron Depot-Ped (leuprolide acetate) prescribing information. FDA label.
• van der Loos, M. A. T. C., et al. (2022). Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. The Lancet Child & Adolescent Health. source.
• detrans.ai (2026). Detransition statistics from /r/detrans stories. stats page.